Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alligator Bioscience AB ( (SE:ATORX) ) just unveiled an update.
Alligator Bioscience recently held an R&D event highlighting significant progress in its clinical-stage antibody drug, mitazalimab, which is now ready for Phase 3 trials in metastatic pancreatic cancer. The company also announced the entry of the HER2 antibody HLX22 into a global Phase 3 trial for gastric cancers, with potential financial benefits from future royalties. These developments position Alligator Bioscience for strategic growth and expanded clinical applications, potentially enhancing its market presence and financial performance.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company based in Lund, Sweden, focusing on developing clinical-stage tumor-directed antibody drugs targeting the CD40 receptor. This approach aims to enhance T cell priming and counteract the immunosuppressive tumor microenvironment, offering potential benefits for cancer patients across various cancer types. The company is publicly listed on Nasdaq Stockholm under the ticker ATORX.
Average Trading Volume: 430,966
Technical Sentiment Signal: Sell
Current Market Cap: SEK164.1M
Learn more about ATORX stock on TipRanks’ Stock Analysis page.